Vistagen Therapeutics, Inc. announced on April 22, 2026, that it received an FDA ‘Study May Proceed’ letter for its refisolone nasal spray, enabling further Phase 2 clinical development for treating menopausal hot flashes. This follows successful Phase 2a studies previously conducted in Mexico.